Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
04/22/2019
Trade Name:
Corlanor Oral Solution
Generic Name or Proper Name (*):
ivabradine
Indications Studied:
Treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate
Label Changes Summary:
*Safety and effectiveness have been established in pediatric patients age 6 months to less than 18 years old and are supported by pharmacokinetic and pharmacodynamic trials and evidence from adequate and well-controlled trials of Corlanor in adult patients. *The pediatric study included 116 patients in the following age groups: 17 patients in the 6 months to less than 12 months age group, 36 patients in the 1 year to less than 3 years age group, and 63 patients in the 3 years to less than 18 years age group. *Safety and efficacy have not been established in patients less than 6 months of age. *Bradycardia and first-degree heart block were observed in pediatric patients treated with Corlanor. *Asymptomatic and symptomatic bradycardia were observed in 6.8% and 4.1% of pediatric patients treated with Corlanor, respectively. *Phosphenes were observed in pediatric patients treated with Corlanor. *Information on dosing, adverse reactions, PK parameters and clinical trial. *New dosage form.
Product Labeling:
[INVALID]
BPCA(B):
B
Sponsor:
Amgen
Pediatric Exclusivity Granted Date:
03/30/2019
NNPS:
FALSE
Therapeutic Category:
Heart failure
-
-